0001231919-26-000465.txt : 20260507 0001231919-26-000465.hdr.sgml : 20260507 20260507162431 ACCESSION NUMBER: 0001231919-26-000465 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260507 DATE AS OF CHANGE: 20260507 EFFECTIVENESS DATE: 20260507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Outlook Therapeutics, Inc. CENTRAL INDEX KEY: 0001649989 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 383982704 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-583245 FILM NUMBER: 26953925 BUSINESS ADDRESS: STREET 1: 111 S. WOOD AVENUE STREET 2: UNIT #100 CITY: ISELIN STATE: NJ ZIP: 08830 BUSINESS PHONE: 6096193990 MAIL ADDRESS: STREET 1: 111 S. WOOD AVENUE STREET 2: UNIT #100 CITY: ISELIN STATE: NJ ZIP: 08830 FORMER COMPANY: FORMER CONFORMED NAME: Oncobiologics, Inc. DATE OF NAME CHANGE: 20150804 D 1 primary_doc.xml X0708 D LIVE 0001649989 Outlook Therapeutics, Inc. 111 S. WOOD AVENUE UNIT #100 ISELIN NJ NEW JERSEY 08830 6096193990 DELAWARE Oncobiologics, Inc. Corporation true Randy H. Thurman c/o Outlook Therapeutics, Inc. 111 South Wood Avenue, Unit #100 Iselin NJ NEW JERSEY 08830 Director Yezan Haddadin c/o Outlook Therapeutics, Inc. 111 South Wood Avenue, Unit #100 Iselin NJ NEW JERSEY 08830 Director Kurt J. Hilzinger c/o Outlook Therapeutics, Inc. 111 South Wood Avenue, Unit #100 Iselin NJ NEW JERSEY 08830 Director Lawrence A. Kenyon c/o Outlook Therapeutics, Inc. 111 South Wood Avenue, Unit #100 Iselin NJ NEW JERSEY 08830 Executive Officer Director Faisal G. Sukhtian c/o Outlook Therapeutics, Inc. 111 South Wood Avenue, Unit #100 Iselin NJ NEW JERSEY 08830 Director Andong Huang c/o Outlook Therapeutics, Inc. 111 South Wood Avenue, Unit #100 Iselin NJ NEW JERSEY 08830 Director Gerd Auffarth c/o Outlook Therapeutics, Inc. 111 South Wood Avenue, Unit #100 Iselin NJ NEW JERSEY 08830 Director Julian Gangolli c/o Outlook Therapeutics, Inc. 111 South Wood Avenue, Unit #100 Iselin NJ NEW JERSEY 08830 Director Biotechnology Decline to Disclose 06b false 2026-04-23 false true true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 Park Avenue 3rd Floor New York NY NEW YORK 10022 IL ILLINOIS NY NEW YORK false 5000000 0 5000000 The total offering amount above represents the amount, if any, that the Issuer could receive if all of the issued Warrants were exercised. As of the date of this filing, none of the warrants have been exercised. false 2 0 485000 0 false Outlook Therapeutics, Inc. /s/ Lawrence Kenyon Lawrence Kenyon Interim Chief Executive Officer, CFO, Treas & Sec'y 2026-05-07